The formamidopyrimidine DNA glycosylase (Fpg) and human 8-oxoguanine DNA glycosylase (hOGG1)-modified comet assays have been widely used in human biomonitoring studies. The purpose of this article is to assess differences in reported levels of Fpg-and hOGG1-sensitive sites in leukocytes and suggest suitable assay controls for the measurement of oxidatively damaged DNA. An assessment of the literature showed a large variation in the reported levels of Fpgsensitive sites (range 0.05-1.31 lesions/10 6 bp). The levels of Fpg-sensitive sites are lower in studies where Fpg has been obtained from commercial suppliers or unknown sources as compared to Fpg from one particular non-commercial source (χ 2 = 7.14, P = 0.028). The levels of hOGG1-sensitive sites are lower (range: 0.04-0.18 lesions/10 6 bp in leukocytes) compared to the Fpg-sensitive sites. Surprisingly, few publications have reported the use of oxidising agents as assay controls, with the exception of hydrogen peroxide. This may be due to a lack of consensus about suitable controls for the Fpg-and hOGG1-modified comet assay. A major challenge is to find an oxidising agent that only oxidises nucleobases and does not generate DNA strand breaks because this reduces the dynamic range of Fpg-and hOGG1-sensitive sites in the comet assay. Based on a literature search we selected the photosensitiser Ro19-8022 plus light, KBrO 3 , 4-nitroquinoline-1-oxide, Na 2 Cr 2 O 7 and ferric nitrilotriacetate as possible assay controls. A subsequent assessment of these compounds for generating cryopreserved assay controls in mononuclear blood cells showed that Ro19-8022 plus light, KBrO 3 and 4-nitroquinoline-1-oxide provided suitable assay controls. We recommend these compounds as comet assay controls for oxidatively damaged DNA.
Introduction
The comet assay has become a popular method in genetic toxicology and human biomonitoring as exemplified by a recent bibliometric analysis that demonstrated a worldwide distribution in the use of the technique (1) . Measurements of DNA strand breaks by the standard comet assay is still the most frequently used version of the technique and this has been adopted by the Organisation for Economic Co-operation and Development (OECD) as Guideline Test No. 489 for the 'in vivo mammalian alkaline comet assay' (2) . Measurement of oxidatively damaged DNA and repair activity has been used in fewer laboratories than the standard comet assay for measurement of DNA strand breaks. It can be argued that the development of the OECD guideline has been driven by a desire to implement the assay in regulatory genotoxicity testing. The sixth international workshop on genotoxicity testing discussed other measures of comet assay endpoints than DNA strand breaks, although there appears to be a lack of enthusiasm for the detection of oxidised nucleobases (3) .
Researchers in academia have promoted the use of comet assay for measurements of other endpoints than DNA strand breaks and initiated various trials to validate the assay. The currently most used modification of the comet assay is the detection of extra lesions by incubation with formamidopyrimidine DNA glycosylase (Fpg), a base excision repair enzyme from Escherichia coli. These lesions are referred to as net Fpg-sensitive sites, when the basal level of DNA strand breaks has been subtracted from the total number of lesions that are detected after incubation with the enzyme. The Fpg-sensitive sites are widely accepted to encompass 8-oxo-7,8-dihydroguanine (8-oxoGua) and certain types of formamidopyrimidine nucleobases (such are produced as breakdown products of 8-oxoGua). The detection of oxidatively damaged DNA is sometimes argued to be unspecific because high concentrations of alkylating agents also generate Fpg-sensitive sites in cell cultures (4) . The human 8-oxoguanine glycosylase (hOGG1) enzyme was suggested to be a suitable replacement for Fpg as it does not recognise alkylated DNA bases in cultured cells (5) . It remains to be determined whether the potential detection of alkylated bases is a significant problem when measuring oxidation damage in other experimental models than cultured cells that are exposed to high concentrations of alkylating agents. One attempt to expand the observations to animal models showed elevated levels of both Fpg-and hOGG1-sensitive sites in the liver of mice after oral exposure to methyl methanesulfonate, which was speculated to be due to oxidative stress (6) .
Procedures for the measurement of oxidatively damaged DNA and repair activity have been described in several reviews (7) (8) (9) . Measurements of oxidatively damaged DNA in human peripheral blood mononuclear cells (PBMCs) have been shown to be a sensitive endpoint in antioxidant and phytochemical supplementation trials, whereas levels of DNA strand breaks are hardly ever altered (10) (11) (12) . Likewise, the enzyme-modified comet assay for measurement of oxidatively damaged DNA has been very popular in particle toxicology (13) (14) (15) (16) (17) , aging (18) and biomonitoring of environmental and occupational exposures (19, 20) .
A close look at publications on oxidatively damaged DNA by the comet assay demonstrates a variation in the reported levels of DNA damage in different biomonitoring studies. This may be related to differences in subtypes of leukocytes, assay procedures as well as differences in DNA damage levels between countries or populations within each country. In this review, we have compared the last decade's reports on oxidatively damaged DNA in leukocytes, lymphocytes and PBMCs. We do not differentiate between types of leukocytes in the present review because several publications do not describe the cell isolation procedure in sufficient detail to allow a precise assessment of the cell types. Notably, this literature review reveals substantial problems with regard to quantitatively comparing results from different publications because of differences in enzyme preparations and a lack of assay controls for the Fpg-or hOGG1-modified comet assay. Thus, the second portion of the review takes the form of an attempt to find suitable assay controls for the comet assay for the detection of oxidatively damaged DNA.
Types of comet assay controls
In the present review, we have distinguished between three different types of control samples (summarised in Table 1) . We have defined an assay control as a cryopreserved sample, which is included in every comet assay experiment. This sample can be used to standardise results within the study if there is too large inter-day variation in the DNA damage analysis ('study' is here defined as a set of comet assay 'experiments'). This type of sample differs from a positive control, which typically is a separate exposure group that has been treated with a known DNA damaging compound. The same chemical can be used as both assay and positive control in the standard (e.g. H 2 O 2 as control for generation of DNA strand breaks) or enzyme-modified comet assay (e.g. KBrO 3 as control for oxidatively damaged DNA) in cell cultures and animal models. However, biomonitoring studies do not have a positive control as humans cannot be exposed well-known genotoxic agents. The comet assay analysis may also include calibration curve samples, which have been treated with different doses of ionising radiation. These samples can be used to transform the primary comet assay descriptor (e.g. %DNA in tail) to number of lesions per unaltered nucleotides or basepairs (bp). This is possible because there is a well-known relationship between the dose of ionising radiation and generation of DNA strand breaks. Calibration curve samples can be regarded as a tool for assessment of external validity (i.e. inter-laboratory comparison), whereas positive controls and assay controls are used for assessment of internal validity (intra-laboratory comparison). Nevertheless, if standardised protocols are used, data from such assay controls might also serve to explain differences in levels between different studies.
In comparison to the primary comet assay descriptors, transformed descriptors (e.g. lesions/10 6 bp) provides a more meaningful information about the (presumably) true frequency of DNA lesions, showing that DNA damage is a rather infrequent event and the comet assay is truly a very sensitive technique. In addition, the individual laboratories can use whatever primary comet assay descriptor they like as long as the final result is expressed as e.g. lesions/10 6 bp after calibration with samples exposed to ionising radiation (21) .
Validation of the enzyme-modified comet assay
The first attempt to validate the Fpg-modified version of the comet assay was carried out by the European Standards Committee on Oxidative DNA Damage (ESCODD) about two decades ago. This project's main aim was to establish the true basal level of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) in human cells because the reported values differed by several orders of magnitude. It appeared to depend on the type of assay that was used. At the time of the ESCODD studies, the Fpg-modified comet assay was a fairly new technique. It is only fair to mention that profound problems were discovered in the measurement of Fpg-sensitive sites as only 3 out of 10 laboratories were able to detect a difference in DNA damage between coded samples that had been treated with different concentrations of the photosensitiser Ro19-8022 plus light (22, 23) . The same trial also showed that the inter-laboratory variation in reported levels of Fpg-sensitive sites in PBMCs could be explained by differences in assay procedures, despite an attempt to standardise these procedures between laboratories (24) . Nevertheless, the observations of lower levels of Fpg-sensitive sites as compared to measurements of 8-oxodG by chromatographic techniques led to the suggestion that the true level of oxidised guanines was approximately one lesion to a million unaltered guanines and certain procedures for chromatographic assays were associated with spurious oxidation of DNA (22) .
The observation from ESCODD encouraged certain laboratories to implement reference standards, using cells that were exposed to ionising radiation, to ameliorate the inter-observer and intralaboratory variation in DNA damage levels (25) (26) (27) . This principle was the foundation for the inter-laboratory European Comet Assay Validation Group (ECVAG), an inter-laboratory validation trial with focus especially on measurement of oxidatively damaged DNA in PBMCs (28) . Ro19-8022 plus light was also the compound of choice in the ECVAG trials to generate Fpg-sensitive sites in cell lines or PBMCs. The ECVAG trails showed that the situation had improved since the ESCODD trial as the large majority of laboratories were able to detect concentration-dependent DNA strand breaks and Fpg-sensitive sites in coded samples (29, 30) . Attempts to alleviate inter-laboratory variation in levels of DNA damage by use of calibration curves was somewhat below expectation (31) (32) (33) . Likewise, an attempt to standardise the measurement of DNA repair incision activity showed a large inter-laboratory variation in the results (34) .
It should be noted that all laboratories in the ESCODD and ECVAG trials used Fpg from the same non-commercial source (i.e. Andrew Collins, Rowett Research Institute, Scotland and later University of Oslo, Norway), although the batches of enzyme might have been different between the ESCODD and ECVAG trials. We refer to this preparation as Fpg from 'Collins' rather than 'noncommercial supplier' because the latter description may be misinterpreted as non-validated enzyme preparation. Fpg from commercial suppliers and hOGG1 have not been validated in multi-laboratory trials.
Collectively, the ESCODD and ECVAG trials demonstrated variations in reported values of Fpg-sensitive sites in coded samples that could be attributed to laboratory procedures despite attempts to standardise the assay conditions. The work has been based on oxidatively damaged DNA in cells after exposure to Ro19-8022 plus light, which generated both 8-oxodG and Fpg-sensitive sites. The inter-laboratory validation of the enzyme-modified comet assay is currently based on Fpg from one supplier and Ro19-8022 as an photosensitiser.
Assessment of variation in reported DNA damage levels between publications
We searched the PubMed database for human biomonitoring studies that have used either the Fpg-or hOGG1-modified comet assay for measurement of oxidatively damaged DNA in leukocytes, lymphocytes or PBMCs. Only studies that have reported oxidatively damaged DNA as lesions/10 6 bp, lesions/10 9 Dalton DNA, %DNA in tail or visual classification (i.e. five-class comet classification system) have been included in the review. We only selected publications from 2006 to 2016, because the earlier publications have already been summarised with respect to levels of oxidatively damaged DNA in leukocytes, lymphocytes and PBMCs (35) .
The PubMed search yielded a total of 90 studies for the analysis. Seventy studies were included in the analysis, whereas 20 studies were excluded for various reasons. The included studies and reasons for excluding specific studies are described in Supplementary Table 1. All primary comet assay descriptors (i.e. %DNA in tail and visual classification) have been transformed to lesions/10 6 bp by use of the ECVAG calibration curve as described previously (36) . A calibration curve does not exist for other primary comet assay descriptors (e.g. tail length and tail moment), although it can easily be made in laboratories that insist on using these primary comet assay descriptors. It should be noted that we only use the ECVAG calibration curve to transform the different primary comet assay descriptors to the same descriptor (i.e. lesions/10 6 bp), whereas it does not correct for differences in laboratory procedures. It is only possible to correct for differences in laboratory procedures if the calibration curves have been made in each of the laboratories. The ECVAG calibration curve is based on results from several laboratories in the ECVAG study and the calibration that was used in ESCODD. In this calibration curve, 1% DNA in tail corresponds to 0.0273 lesions/10 6 bp. Figure 1 depicts the levels of Fpg-sensitive sites in leukocytes, lymphocytes or PBMCs in studies from 2006 to 2016. The results demonstrate a large spread in the reported levels of Fpg-sensitive sites in human leukocytes, lymphocytes or PBMCs (range: 0.05-1.31 lesions/10 6 bp). Table 2 shows the results, reported in parametric (mean and 95% CI) and non-parametric scale (median and quartiles). It appears that slightly higher levels of Fpg-sensitive sites have been reported in recent years (i.e. 0.35 lesions/10 6 bp, 95% CI: 0.27-0.43 lesions/10 6 bp) as compared to the older literature (0.28 lesions/10 6 bp, 95% CI: 0.20-0.36 lesions/10 6 bp). However, the most striking observation is that studies using other Fpg enzyme sources (i.e. Trevigen, New England Biolabs and unknown) than the sample from Collins have predominantly reported low values of Fpgsensitive sites. An analysis of the proportion of studies in the lower (9 other versus 7 Collins), middle (9 other versus 21 Collins) and upper (2 other versus 14 Collins) quartiles demonstrates a highly significant difference in the distribution. Studies with Fpg from other sources than Collins have reported low levels of Fpg-sensitive sites (χ 2 = 7.14, P = 0.028). None of the studies using commercial or unknown Fpg preparations have reported results from reliable assay controls (see Supplementary Table 1 for information about assay controls in each study). The difference between Fpg preparations might be due to the specific activity of the enzyme or the total amount of enzyme that is applied onto the gels before the incubation. However, it is not possible to assess these factors in a systematic way because several publications have not specified the amount of enzyme for the Fpg treatment. Figure 2 shows the results from biomonitoring studies that have reported hOGG1-sensitive sites (range: 0.04-0.18 lesions/10 6 bp). Enzymes from Trevigen, Sigma and New England Biolabs have been used in the studies. The latter is the most frequent supplier (8 out of 11 studies). The level of hOGG1-sensitive sites is 4-fold lower than the levels of Fpg-sensitive sites from studies using Fpg from Collins ( Table 2) . Only one laboratory has used both Fpg from Collins and hOGG1 from New England Biolabs; results from three studies demonstrated lower levels of hOGG1-sensitive sites as compared to Fpgsensitive sites in human PBMCs (37) (38) (39) .
Collectively, the results from human biomonitoring studies demonstrate a large spread in the reported values of Fpg-and hOGG1-sensitive sites. The variation in levels of Fpg-sensitive sites can be ascribed to the enzyme preparation; using Fpg from Collins appears to give rise to higher reported levels of DNA damage. Further studies are warranted to assess whether the discrepancy is due to differences in enzyme activity or unspecific nuclease activity. All studies have consistently reported lower levels of hOGG1-sensitive sites than Fpg-sensitive sites.
Use of assay controls in biomonitoring and other studies
The use of assay controls for the enzyme-modified comet assay might be standard practice, although surprisingly few publications actually show these results. It is likely that earlier reports did not use proper assay controls for the enzyme-modified comet assay because there was not a well-validated control for the detection of oxidatively damaged DNA. ESCODD used Ro19-8022 plus light as assay control, but the compound was not easy to obtain in the early 2000s.
One of the most widely used assay controls for the standard comet assay is H 2 O 2 . However, the concurrent generation of DNA strand breaks makes it difficult to measure high levels of enzymesensitive sites due to saturation of the assay. This problem can be alleviated by using a short-term post-exposure incubation period because the DNA strand breaks are repaired much faster than Fpgsensitive sites (40) . However, it appears that studies using H 2 O 2 as assay/positive control have not used the post-exposure incubation period. We have not done a formal literature search for studies using H 2 O 2 as assay/positive control because this compound has no future as a true assay control for the Fpg-or hOGG1-modified comet assay (Supplementary Table I lists the assay controls in the biomonitoring studies). Of the biomonitoring studies we have included, 5 reported the use of H 2 O 2 , 9 Ro19-8022 plus light, while 56 studies did not report the use of assay controls. Table 3 shows the results from studies where Ro19-8022 plus light and KBrO 3 have been used as assay controls in biomonitoring or other studies that have used the enzyme-modified comet assay. The table demonstrates that the majority of studies have reported lower levels of hOGG1-sensitive sites than Fpg-sensitive sites in Ro19-8022 plus light and KBrO 3 assay controls (e.g. 8 out of 11 studies showed that the level of Fpg-sensitive sites is 50% higher Levels of Fpg-sensitive sites in older studies have previously been reported (35) , whereas levels of hOGG1-sensitive sites have not been summarised in previous studies. The results can be transformed to %DNA in tail by using the ECVAG calibration curve where 0.1 lesions/10 6 bp corresponds to 3.7% DNA in the tail. than hOGG1-sensitive sites). Special attention should be paid to reports from two large biomonitoring studies that used Ro19-8022 plus light as assay control (37, 41 (41) . These observations are similar to another large study on Ro19-8022 plus light (1.07 lesions/10 6 bp SD = 0.17 lesions/10 6 bp) in assay controls from 39 independent experiments (37). The coefficient of variation is approximately 15% in these two studies, which is likely to be a realistic estimate of the assay variation.
In search of suitable assay controls for the Fpg-and hOGG1-modified comet assays The results have been recalculated to first arbitrary units in 0-400 scale and then converted to lesions/10 6 bp by use of the ECVAG calibration curve.
c Mean of Fpg-sensitive sites in different laboratories. The study also analysed samples that were exposed to 0.2 µM of Ro19-8022 plus light, which yielded a level of 0.69 ± 0.28 lesions/10 6 bp (mean results from laboratories that participated in the ECVAG trial). The DNA damage level has been selected from the lowest concentration from the plateau of Fpg-sensitive sites, which occurred at 50% DNA in tail. A slightly increased level of hOGG1-sensitive sites was observed at higher concentrations (0.35 lesions/10 6 bp). The results is the mean from PBMCs that were isolated by two different procedures.
No 66-27-3), N-Methyl-N′-nitro-N-nitrosoguanidine (CAS No: 70-25-7), 1,2-dimethylhydrazine (CAS Ro 306-37-6) or N-methyl-N-nitrosourea (CAS No 684-93-5)
. The choice of compound may depend on the tissue being examined for DNA strand breaks as they have target tissue-specific genotoxicity profiles.
Alkylating agents are frequently used as controls for the Fpgmodified comet assay or even hOGG1-modified assay. One might suspect the use of alkylating agents is related to the recommendation of these agents in the OECD guideline for the in vivo comet assay as positive controls for DNA strand breaks. However, alkylating agents are not the logical choice for positive controls for the hOGG1-modified comet assay and their use in the Fpg-modified assay appears to be based on the notion that the enzyme detects certain kinds of alkylated formamidopyrimidine lesions.
We have searched the literature in an attempt to identify a suitable assay control for the Fpg-and hOGG1-modified comet assay. The search clearly demonstrates that reporting results on assay controls is not standard practice, although this cannot be taken as proof that the researchers have not included controls in the analysis of DNA damage. The selection criteria for ideal assay controls are that the compound should: (i) induce oxidised DNA bases with little concurrent generation of DNA strand breaks, (ii) be suitable for in vivo dosing and (iii) be a direct-acting genotoxic compound. Five compounds fulfil at least some of these criteria. The compounds are discussed in detail below and summarised in Table 4 .
Ro19-8022 plus light
The compound was originally developed by F. Hoffmann-La Roche as an anxiolytic drug. It was discovered to be a photosensitiser that together with light generated a DNA damage profile, which is similar to that of singlet oxygen (42) . The compound is an ideal genotoxic agent because cells can be loaded with Ro19-8022 in the dark before they are irradiated with light. The photochemical reaction is terminated once the light source is switched off. Thus, the period of the DNA oxidation reaction can be controlled. In comparison, direct-acting oxidising chemicals may continue to oxidise DNA in subsequent steps of cell isolation and the comet assay procedures. In addition, Ro19-8022 does not require metabolic activation and it has not been described to interact with cellular components. Therefore, it is a suitable DNA damaging compound in a wide range of cells. The concentration-response curves of Ro19-8022 plus light generated DNA damage typically use the molar concentration as independent variable, whereas the irradiation time is typically omitted. In our hands, Ro19-8022 plus light is a reliable compound for generation of Fpg-sensitive sites, but the irradiation of cell suspensions with light generates heat. Care has to be taken to avoid heating of the cell suspensions because it will generate DNA strand breaks. We irradiate the cells on ice. Thus, the irradiation time is typically kept as short as possible (4 min in our protocol). The irradiation time, light intensity and concentration of Ro19-8022 are determinants for the generation of oxidatively damaged DNA and standardisation of these factors are required in case the results on Ro19-8022 exposed cells are directly compared between laboratories.
The Ro19-8022 photosensitiser has been used mainly by laboratories that have participated in the ESCODD and ECVAG validation trials. A widespread use might have been hampered by the availability of the compound, although F. Hoffmann-La Roche has distributed it as a gift to researchers. Ro19-8022 plus light Exposure in animal models includes acute (i.e. single-dose and sacrifice within 24 h after administration) and long-term exposure (i.e. repeated dosing over several days or weeks).
was used as compound for the production of both 8-oxodG and Fpg-sensitive sites in the ESCODD inter-laboratory validation trial. The Fpg-modified comet assay results demonstrated a linear concentration-response relationship in the coordinating laboratoryapproximately 0.26, 0.47 and 0.64 lesions/10 6 bp in controls, 0.2 and 0.4 µM Ro19-8022 plus light, respectively (23) . Another study by the same group showed that the production of Fpg-sensitive sites increased to 1.04 lesions/10 6 bp after exposure to 0.6 µM of Ro19-8022 plus light (43) .
The ECVAG trial demonstrated that measurement of Fpgsensitive sites differed substantially between the 10 laboratories that measured Fpg-sensitive sites in cryopreserved lung epithelial A549 cells that had been exposed to Ro19-8022 plus light (0.2 µM: 0.69, lesions/10 6 bp, SD = 0.28 lesions/10 6 bp and 0.8 µM: 1.41 lesions/10 6 bp, SD = 0.43 lesions/10 6 bp) (30) . Recent studies have also demonstrated concentration-response relationships between Ro19-8022 plus light (0.1-0.6 µM) and Fpg-sensitive sites in A549 and bronchial epithelial cells (BEAS-2B) lung cells (44) .
There are substantially fewer studies on Ro19-8022 plus light generated hOGG1-sensitive sites as compared to Fpg-sensitive sites. We have observed that the level of hOGG1-sensitive sites is lower than Fpg-sensitive sites in the same cells treated with Ro19-8022 plus light (37, 38, (45) (46) (47) . The reason for this difference is unknown, but it should be noted that some experiments have shown identical levels of Fpg-and hOGG1-sensitive sites in KBrO 3 -treated cells (6, 48) , indicating that the low level of hOGG1-sensitive sites in Ro19-8022 plus light treated cells is not due to an inefficient enzyme. In addition, it has been estimated that 74% of the Fpg-sensitive sites are 8-oxodG (49) , which is efficiently recognised by hOGG1. The discrepancy between the hOGG1-and Fpg-modified comet assays on Ro19-8022 plus light treated cells should be investigated further before Ro19-8022 plus light, rather than KBrO 3 , can be recommended as assay control for the hOGG1-modified comet assay. It should also be noted that Ro19-8022 is not a suitable positive control for the in vivo comet assay because very few tissues can be irradiated with light to generate oxidised DNA bases.
KBrO 3
This compound has been shown to induce both 8-oxodG and Fpg-sites in Chinese hamster (V79) lung cells (50) . Two later studies by the same research group have used %DNA in tail as comet assay descriptor and shown increased levels of Fpg-sensitive sites in PBMCs after exposure to 10 mM of KBrO 3 ; re-calculation of the Fpg-sensitive sites yields 0.25 and 1.05 lesions/10 6 bp in the two studies (51, 52) . KBrO 3 has been shown to induce Fpg-and hOGG1-sensitive sites in mouse lymphoma L5178Y, TK6 and monocytic THP-1 cells, with little concurrent generation of DNA strand breaks (5, 6, 53, 54) . In addition, there were inductions of hOGG1-sites and 8-oxodG in human bronchoalveolar (H358) cells (55) .
It has been shown that KBrO 3 induced 8-oxodG in the kidneys of both mice and rats that were exposed via the drinking water, although it appeared to take several weeks before the 8-oxodG levels increased above levels in unexposed animals (56, 57) . Administration of KBrO 3 to the drinking water has also been shown to be associated with a modest increase in hepatic levels of 8-oxodG in mice (58) . A recent study used oral exposure to KBrO 3 (400 mg/kg, 4-h postexposure time) as in vivo positive control in the liver and kidney of rats in a study that showed weak genotoxic responses of silica nanomaterials (59) .
Collectively, KBrO 3 has been shown to induce both Fpg-and hOGG1 sensitive sites in various cell types and the genotoxicity has been documented in several independent laboratories. In addition, there are independent studies that have shown induction of 8-oxodG in cells after exposure to KBrO 3 . This compound can be recommended as an assay control for both Fpg-and hOGG1 sensitive sites in the comet assay. KBrO 3 should be a suitable candidate as in vivo positive control for both the Fpg-and hOGG1-modified comet assay.
4-Nitroquinoline-1-oxide (4NQO)
One experiment showed a concentration-dependent increase in Fpgsensitive sites in TK6 cells. The highest concentration (0.4 µM, 3 h incubation) produced a net increase of 0.78 lesions/10 6 bp with little concurrent generation of DNA strand breaks (60) . In another study, it has been shown that 4NQO increased the level of 8-oxodG in normal human fibroblasts, although it required concentrations above 1 µM (61).
Na 2 Cr 2 O 7
It has been shown that exposure to Na 2 Cr 2 O 7 (10 µM for 1 h) increased the level of Fpg-sensitive sites in A549 cells from 0.03 to 0.17 lesions/10 6 bp (62). Expressed as %DNA in tail the increase was 1.1-6.1; the corresponding levels of DNA strand breaks were 13.1 and 27.9% DNA in tail. Thus, the net increase in Fpg-sensitive sites was modest and it occurred on a background of high levels of DNA strand breaks. The source of Fpg was not reported in the paper, but a later publication from the same group of authors reported Trevigen as the source of Fpg (63) . In the latter study, the level of Fpg-sensitive sites increased from 0.16 to 0.25 lesions/10 6 bp in human lymphocytes after 1 h exposure to 0.1 µM (net increase: 0.09 lesions/10 6 bp or 3.4% DNA in tail). A later study on A549 and BEAS-2B cells demonstrated some cell type and incubation time differences in the generation of Fpg-sensitive sites (64) . This study used Fpg from Sigma. The results did not demonstrate clear concentration-response relationships (0.1-10 µM) and the increased levels of Fpg-sensitive sites coincided with increased levels of DNA strand breaks. The genotoxic effect of Na 2 Cr 2 O 7 has also been investigated in TK6 cells, using Fpg from Collins. Only high concentrations of Na 2 Cr 2 O 7 were used (800 and 1000 µM) and the study did not include a control for Fpg-sensitive sites in unexposed cells (65) . Nevertheless, the results showed the net induction of Fpg-sensitive sites in Na 2 Cr 2 O 7 exposed cells (19 %DNA in tail or 0.52 lesions/10 6 bp, 800 µM) was smaller than the induction of DNA strand breaks (39 %DNA in tail) .
Experimental animal models have demonstrated increased levels of DNA strand breaks in organs after administration of chromium (VI) compounds, whereas the studies on oxidatively damaged DNA in animals are equivocal due to high baseline-levels of 8-oxodG (66) .
Collectively, the results from four published studies suggest that Na 2 Cr 2 O 7 might not be a suitable assay control for the Fpg-modified comet assay because of the concomitant generation of DNA strand breaks.
Ferric nitrilotriacetate (FeNTA)
A solution of FeNTA is typically obtained by mixing ferric ions with disodium nitrilotriacetate. The ratio between ferric ions and disodium nitrilotriacetate differs between studies (typically 1:10 to 1:50 in molar ratio), which may not have an impact on the generation of DNA damage in cells or animals because there is a surplus of nitrilotriacetate metal-chelator.
One study using the comet assay demonstrated a concentrationdependent increase in Fpg-sensitive sites in human colon HT29 cells after 15 min exposure to concentrations up to 1000 µM (67). The net induction at 1000 µM was 0.6 lesions/10 6 bp and there was little induction of DNA strand breaks. The Fpg enzyme was obtained from a reliable source (i.e. Collins). However, it should be noted that at least one study has reported high levels of DNA strand breaks in human leukocytes after exposure to 1000 µM for 30 min (68) . Observations obtained with the use of the alkaline unwinding assay-an assay that is similar to the alkaline comet assay-showed that the Fpg-sensitive sites increased from 0.2 lesions/10 6 bp (unexposed controls) to 1.2 lesions/10 6 bp (1000 µM for 24 h) and 2.0 lesions/10 6 bp (500 µM for 48 h) in V79 cells (69) . FeNTA has been used in animal models for iron-overload, including measurements of 8-oxodG in tissues (70) . The majority of these studies date back to the period of time when the protocols for DNA processing before analysis in chromatographic assays generated spurious oxidation. Notably, one study used an optimised protocol and showed increased levels of 8-oxodG in the kidney of rats at 1 and 6 h after intraperitoneal injection, whereas there were unaltered levels of 8-oxodG in the liver (71) .
Collectively, there are relatively few studies that have used the Fpg-modified comet assay for studies of FeNTA-induced DNA damage and hOGG1 has not been used in this line of research. Results from the literature are too few to assess the suitability of FeNTA as a positive control in vivo for the comet assay.
Assessment of potential assay controls for the Fpgand hOGG1-modified comet assay
In an attempt to assess potential assay controls for the Fpg-and hOGG1-modified comet assay, we measured levels of oxidatively damaged DNA in THP-1 cells after exposure to different oxidising agents (Na 2 Cr 2 O 7 , 4NQO, FeNTA, KBrO 3 ) and photosensitiser (Ro19-8022 plus light). We used THP-1 cells because they have a fairly low basal level of DNA damage, have the same shape as PBMCs (i.e. the nuclei are completely round in the microscope) and do not require special cell culture facility (i.e. classified as biosafety level 1 material). THP-1 cells were exposed to the oxidising agents and cryopreserved in medium containing 50% fetal bovine serum, 40% RPMI medium and 10% dimethyl sulfoxide (see supplement for details on the exposure conditions). Subsequently, cryopreserved samples were processed in the comet assay and scored by the same investigator. The comet assay procedure is described in the supplement (72) . Figure 3 depicts and FeNTA are discouraging because of a lack of concentrationresponse relationship. These compounds do not appear to be ideal candidates as assay controls for the Fpg-and hOGG1-modified comet assay.
Collectively, KBrO 3 , Ro19-8022 plus light and 4NQO are suitable assay controls for the Fpg-modified comet assay, whereas KBrO 3 is a strong candidate as assay control for the hOGG1-modified comet assay.
Discussion
The literature search on the enzyme-modified comet assay demonstrated a large variation in the reported results in biomonitoring studies using leukocytes, lymphocytes and PBMCs. Interestingly, the mean levels of Fpg-sensitive sites in the present and the previous assessment of background levels are almost identical, as is the variation in Fpg-sensitive sites between studies (35) . The type of Fpg Figure 3 . Levels of Fpg-and hOGG1-sensitive sites in human monocytic THP-1 cells that have been exposed to KBrO 3 , 4-nitroquinoline-1-oxide (4NQO), Na 2 Cr 2 O 7 or ferric nitrilotriacetate (FeNTA) and stored as cryopreserved assay controls. The concentrations are reported as low (L), middle (M) and high (H). The cells for the Ro19-8022 plus light cryopreserved assay controls are peripheral blood mononuclear cells because they have been generated for a number of biomonitoring studies. Details of the cell culture experiments are described in the supplement. Symbols and whiskers are the mean and 95% confidence intervals from three independent experiments. All samples were processed in the same comet assay experiment. The comet assay conditions have previously been described (72) . Levels of DNA strand breaks and total number of lesions in enzyme-treated slides are reported in Supplementary Figure 1. preparation appears to have an influence on the level of Fpg-sensitive sites as studies using the Fpg from Collins report higher levels of DNA damage than commercial suppliers or unknown sources. It should be emphasised that there also have been more than one batch of Fpg from Collins, which have some difference in strength or activity (personal communication with Collins and own experience). The group of studies using other sources of Fpg than Collins also includes unknown sources of the enzyme. Andrew Collins has distributed the Fpg enzyme to researchers for free (reasonably, shipment has been at own expense). Thus, we think that researchers who have not specified the source of Fpg most likely have used enzyme from commercial suppliers because Collins, as a courtesy, would have been acknowledged for the gift. We considered comparing the efficiency of the different Fpg preparations in the same experiment, but there is not sufficient information about the amount of enzyme used in the publications. Thus, it is not possible to determine if low levels of Fpg-sensitive sites are due to an inadequate amount of enzyme.
There is variation within the group of studies that have used Fpg from Collins as well as variation in the group of studies that have used other sources of Fpg. This variation might be explained by differences in cell populations (i.e. leukocytes, lymphocytes or PBMCs). However, several publications lack specific information about the cell isolation procedure. The same procedure is described for isolation of lymphocytes and PBMCs in different publications. It is not possible to obtain reliable information about the cell isolation procedures to assess relations to differences in levels of oxidatively damaged nucleobases. There is a paucity of studies investigating differences in oxidatively damaged DNA between subsets of leukocytes or PBMCs, although it could be argued there are more important issues to be solved than differences in DNA damage in subsets of leukocytes. It should also be noted that some studies have measured DNA damage immediately after isolation of leukocytes or PBMCs, whereas others have used cryopreserved cells for later analysis. Also here it is not possible to systematically assess the impact of different cryopreservation protocols because of a lack of information in many studies. The cryopreservation medium differs between studies. It usually contains fetal bovine serum and dimethyl sulfoxide, and sometimes also RPMI1640 medium. One study, using an unusual cryopreservation medium with only phosphate buffer saline with 10% dimethyl sulfoxide, showed very high levels of Fpgsensitive sites (73) . However, it should also be acknowledged that another publication from the same authors showed high levels of Fpg-sensitive sites in fresh samples that had not been cryopreserved (74) . It has been reported that the cryopreservation can increase the level of DNA damage as shown in a study where the level of Fpg-sensitive sites in leukocytes increased from 0.34 lesions/10 6 bp in fresh samples to 0.58 lesions/10 6 bp in cryopreserved samples from the same subjects (75) . However, cryopreservation also offers a possibility to include all samples from the same subject in the same experimental run. Moreover, it is possible to repeat analysis of cryopreserved samples if certain samples are suspected to be outliers. Cryopreservation also alleviates the risk of unequal analysis of samples from cases and controls. Thus, we find that the advantages in cryopreservation outweigh the disadvantages in large biomonitoring studies.
The analysis of assay controls indicated that Ro19-8022 plus light and KBrO 3 were the most promising candidates for the Fpgand hOGG1-modified comet assays. In addition, 4NQO appears to be a good assay control for the Fpg-modified comet assay, although the results indicate that the concentration of 4NQO is a matter of importance. The potential use of KBrO 3 as assay control appears to have been largely ignored, although it was reported in 1999 to generate high levels of Fpg-sensitive sites and little DNA strand breaks in the comet assay (50) . This is similar to earlier studies on KBrO 3 exposure in cultured cells, using the Fpgmodified alkaline elution assay (76) . KBrO 3 has also been used as assay control for the hOGG1-modified comet assay (5). Na 2 Cr 2 O 7 and FeNTA only produced low levels of Fpg-and hOGG1-sensitive sites in THP-1 cells, which did not occur in a concentrationdependent manner.
There is an obvious discrepancy between the levels of Fpg-and hOGG1-sensitive sites in both PBMCs and assay control samples. This is especially noted in the Ro19-8022 plus light-treated cells, whereas KBrO 3 treated cells seem to have more similar levels of Fpgand hOGG1-sensitive sites (Figure 3 ; Table 3 ). In principle, Fpg and hOGG1 should recognise the same types of oxidatively damaged DNA lesions, i.e. 8-oxoGua and formamidopyrimidines. The difference in Fpg-and hOGG1-sensitive sites might be due to other lesions than 8-oxoGua and formamidopyrimidines. Studies on positive controls for the hOGG1-modified comet assay are warranted.
Lastly, our assessment only included the Fpg-and hOGG1-modified comet assays. Using endonuclease III (ENDOIII) from Escherichia coli, the ENDOIII-modified comet assay has been used for the detection of oxidised pyrimidine lesions. This modification of the comet assay has not been subjected to the same rigorous validation as the Fpg-modified comet assay. Some of the oxidising agents in the present paper might be suitable assay controls for the ENDOIIImodified comet assay, although it needs to be tested in further detail. The starting point for validation of the ENDOIII-modified comet assay could be to test or develop proper assay controls.
Conclusion
The Fpg-and hOGG1-modified comet assays offer relevant information as they detect the promutagenic 8-oxoGua lesion. However, there is a need to develop proper assay controls for the Fpg-and hOGG1-modified comet assay. Among different candidates, KBrO 3 appears to be a suitable assay control for the Fpg-and hOGG1-modified comet assay because it produces high levels of oxidatively damaged DNA. Ro19-8022 plus light and 4NQO are useful assay controls for the Fpg-modified comet assay. Na 2 Cr 2 O 6 and FeNTA may not be relevant candidates for further exploration as assay controls, although they may be useful as positive controls in animal experimental models. In any case, we recommend that results from assay controls are reported in publications describing results from the comet assay.
Supplementary data
Supplementary Table 1 and Figure 1 are available at Mutagenesis Online.
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